Description
Survodutide is an investigational, long-acting dual agonist of the glucagon and glucagon-like peptide-1 (GLP-1) receptors. Developed by Boehringer Ingelheim in collaboration with Zealand Pharma, it is administered once weekly via subcutaneous injection. Survodutide is being studied for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). By simultaneously activating glucagon and GLP-1 receptors, survodutide aims to reduce body weight through increased energy expenditure and decreased food intake, while also improving glycemic control and liver health.
| F act Table |
| Formula | C187H291N51O57 |
| License | Investigational (not yet approved) |
| Bioavailability | ~55% (subcutaneous) |
| Legal status | Phase 2/3 clinical trials (obesity, NASH) |
| Chemical Name | Survodutide |
| Elimination half-life | ~6–8 days |
| Dosage (Strength) | Investigated in 1.2–4.8 mg once-weekly subcutaneous injections |
| Pregnancy | Not recommended – investigational, insufficient data |
| Brands | None (investigational) |
| Protein binding | Data not disclosed (likely high due to fatty acid modification) |
| PubChem CID | 137700272 |
| MedlinePlus | Not assigned |
| ChEBI | Not assigned |
| ATC code | None (under investigation) |
| DrugBank | DB16687 |
| KEGG | Not assigned |
| Routes of administration | Subcutaneous (weekly) |
Directions
In clinical trials, survodutide has been administered subcutaneously once weekly at doses ranging from 0.6 mg to 6.0 mg. Treatment typically involves a dose-escalation phase over several weeks to mitigate gastrointestinal side effects, followed by a maintenance phase. Specific dosing regimens are determined based on the indication and patient response. As survodutide is currently investigational, dosing should be guided by clinical trial protocols and under the supervision of qualified healthcare professionals.
Ingredients
Survodutide is a synthetic peptide consisting of 29 amino acids, modified with a C18 fatty acid chain to prolong its half-life, allowing for once-weekly dosing. The formulation details, including excipients and other inactive ingredients, have not been publicly disclosed.
Contraindications
As an investigational agent, comprehensive contraindication profiles for survodutide have not been fully established. However, individuals with known hypersensitivity to survodutide or any of its components should avoid use. Caution is advised in patients with a history of pancreatitis or severe gastrointestinal disorders. Participation in clinical trials may have specific inclusion and exclusion criteria to ensure patient safety.
Cautions
Survodutide treatment has been associated with gastrointestinal adverse events, particularly during the dose-escalation phase. Patients should be monitored for signs of nausea, vomiting, and diarrhea. Caution is advised in individuals with hepatic impairment, as the drug's effects on liver function are still under investigation. Regular monitoring of liver enzymes and renal function is recommended during treatment. As with other GLP-1 receptor agonists, there may be an increased risk of thyroid C-cell tumors; however, this risk has not been confirmed in humans.
Side Effects
Common side effects observed in clinical trials include:
These gastrointestinal symptoms are typically mild to moderate in severity and tend to occur during the initial dose-escalation phase. In some cases, these side effects have led to treatment discontinuation. Serious adverse events are rare but have included dehydration and renal impairment secondary to gastrointestinal losses.
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14562
Prescription Required